clinical

Clinical research

An 8-week dose comparison pilot study was conducted in 22 postmenopausal women (natural or surgical menopause ≥1 year; age 50-75 years; BMI ≥25 and ≤35 kg/m2).1 Women were randomized into two groups – 36 mg/day and 72 mg/day doses of HMRlignan. Daily hot flash diaries were completed throughout the study.

Compared to baseline (pre-treatment), women taking 72 mg of HMRlignan™ per day had a significant reduction in the number of hot flashes after just 4 weeks (55%; p= 0.009). At 8 weeks, the mean reduction in daily hot flashes was 50% (p = 0.025). Women taking 72 mg/day noted 79% fewer severe hot flashes compared to baseline at week 4 (p < 0.001) and 80% fewer at week 8 (p < 0.001). No significant side effects or safety issues were identified in the study.

 
1. Udani JK, Brown DJ, Tan MOC, Hardy M. Pharmacokinetics and bioavailability of plant lignin 7-hydroxymatairesinol and effects on serum enterolactone and clinical symptoms in postmenopausal women: A single-blinded, parallel, dose-comparison study. J Amer Coll Nutr 2013;32:428-35.